The traditional path of de novo drug discovery is often described as a grueling marathon, a journey characterized by astronomical […]

1. The Asset Management View of Litigation In the pharmaceutical industry, the expiration of a primary patent is not merely

The Imperative for an Evolved Generic Strategy: A New Paradigm of Value In the intricate ecosystem of modern healthcare, the

Introduction: The High-Stakes Battlefield of Generic Drug Market Entry For a pharmaceutical company, the journey to market is a strategic

Executive Summary The global pharmaceutical market presents two primary avenues for investors seeking to capitalize on the expiration of brand-name

The New Mandate: Understanding China’s IP Transformation For years, the narrative surrounding intellectual property in China has been one of

Introduction: Why Patent Intelligence is the Cornerstone of Market Access Strategy In the high-stakes arena of the global pharmaceutical industry,

In pharmaceuticals no event looms larger or casts a longer shadow than the patent cliff. It is a moment of

Litigation Summary and Analysis: Bayerische Motoren Werke Aktiengesellschaft v. Onesta IP, LLC (26-1338) Executive Summary Bayerische Motoren Werke Aktiengesellschaft (BMW)